Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 6 participants
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Wichita, Kansas • Oklahoma City, Oklahoma • Jenkintown, Pennsylvania + 1 more

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: QLS-101, Timolol Maleate; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Albany, Georgia

Conditions: Primary Open Angle Glaucoma
Interventions: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery; Device · Procedure
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions: Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: iStent, Cataract surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 14
States / cities: Irvine, California • Montebello, California • Aurora, Colorado + 11 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Artesia, California • Pasadena, California • San Francisco, California + 3 more

Conditions: Open Angle Glaucoma (OAG), Glaucoma
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 23
States / cities: Artesia, California • Newport Beach, California • Petaluma, California + 17 more

Conditions: Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions: SHP639 (n=60), Placebo Comparator (n=24); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Open-angle Glaucoma
Interventions: Hydrus Microstent, Ophthalmic surgery; Device · Procedure
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
Interventions: QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Fayetteville, Arkansas • Newport Beach, California • Petaluma, California + 8 more

Conditions: Open Angle Glaucoma
Interventions: CycloPen Cyclodialysis System; Device
Lead sponsor: Iantrek, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: SPARC0912, Reference0912; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Primary Open Angle Glaucoma (POAG)
Interventions: Direct Selective Laser Trabeculoplasty; Device
Lead sponsor: Select Eye Care; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Elkridge, Maryland

Conditions: Open Angle Glaucoma
Interventions: Cosopt, Xalatan; Drug
Lead sponsor: Advanced Glaucoma Specialists; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Reading, Massachusetts

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost punctal plug, artificial tears preserved with Benzalkonium Chloride; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: SPARC0913; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Glaucoma, Open-Angle
Interventions: H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]; Drug
Lead sponsor: Allysta Pharmaceutical; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Primary Open Angle Glaucoma
Interventions: dietary supplement with antioxidants, Placebo; Dietary Supplement
Lead sponsor: ScienceBased Health; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 1,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Murfreesboro, Tennessee

Conditions: Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Treatment of Failing Blebs With Ranibizumab

A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Hydrus Microstent for Refractory Open-Angle Glaucoma

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

H-1337 Ophthalmic Solution Phase 1/2

The Effects of an Antioxidant Formulation on Ocular Blood Flow

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma